Skip to main content
Saniona logo

Saniona — Investor Relations & Filings

Ticker · SANION ISIN · SE0005794617 LEI · 549300XO4L9XNOCFCZ84 ST Manufacturing
Open in API
Filings indexed 298 across all filing types
Latest filing 2021-04-22 Share Issue/Capital Cha…
Country SE Sweden
Listing ST SANION

About Saniona

http://saniona.com

Saniona is a clinical-stage biopharmaceutical company focused on the research and development of treatments for neurological disorders, with a primary emphasis on epilepsy. The company is a leader in the field of ion channel modulation, leveraging its expertise and a proprietary drug discovery engine to create new medicines. Saniona has developed an extensive library of over 20,000 proprietary molecules designed to target various ion channels. Its pipeline includes multiple potential new medicines advancing through clinical trials, with the goal of addressing unmet medical needs for patients with central nervous system diseases.

Recent filings

Filing Released Lang Actions
Saniona announces outcome of TO3 warrant exercise
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing the outcome of a warrant exercise (TO3 warrants) and the subsequent issuance of new shares. It details the number of warrants exercised, the proceeds received, and the resulting change in the total number of shares and share capital. This falls under the category of share issuance and capital changes.
2021-04-22 English
Saniona meddelar utfall i inlösen av teckningsoptioner TO 3
Share Issue/Capital Change Classification · 95% confidence The document is a press release announcing the outcome of a warrant exercise (TO 3) for Saniona. It details the number of warrants exercised, the capital raised, and the resulting change in the total number of shares and share capital. This falls under the category of capital changes and share issuance resulting from financial instruments.
2021-04-22 Swedish
Saniona uppdaterar tidsplanerna för den kliniska utvecklingen av Tesomet baserat på besked om tillverkningen från FDA
Regulatory Filings Classification · 95% confidence The document is a press release from Saniona regarding regulatory feedback from the FDA concerning the manufacturing process (CMC) of their drug candidate, Tesomet. It details how this feedback impacts the timeline for clinical trials. This is a corporate announcement regarding operational and regulatory developments, which falls under the 'Regulatory Filings' category as it does not fit into specific financial reporting or governance categories.
2021-04-22 Swedish
Saniona Updates Tesomet Clinical Development Timelines Based on Manufacturing Feedback from U.S. FDA
Regulatory Filings Classification · 95% confidence The document is a press release from Saniona regarding clinical development timelines for their drug candidate, Tesomet, following feedback from the U.S. FDA. It discusses regulatory interactions, manufacturing plans, and the impact on clinical trial schedules. As it is a general corporate announcement regarding regulatory and operational updates that does not fit into specific categories like financial reports, dividends, or board changes, it falls under the 'Regulatory Filings' (RNS) category.
2021-04-22 English
Saniona meddelar att nyttjandeperioden för teckningsoptioner av serie TO3 inleds den 6 april 2021
Share Issue/Capital Change Classification · 95% confidence The document is a press release from Saniona announcing the start of the exercise period for their TO3 series warrants. It details the exercise price, the timeline for the exercise period, instructions for shareholders on how to exercise their warrants, and the impact on the company's share capital. This falls under the category of capital structure changes and financing activities related to warrants/share issues.
2021-03-31 Swedish
Saniona announces that the exercise period of warrants of series TO3 begins on April 6, 2021
Share Issue/Capital Change Classification · 95% confidence The document is a press release from Saniona announcing the commencement of an exercise period for warrants (series TO3). It details the subscription price, the timeline for exercise, and instructions for shareholders on how to participate in the warrant exercise. This falls under the category of capital structure changes and financing activities related to share issuance.
2021-03-31 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.